Status:
RECRUITING
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
HNSCC
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages. Dif...
Eligibility Criteria
Inclusion
- Patients treatable for HNSCC (palliative), NSCLC (separately palliative and adjuvant) or "other solid tumour"
- Indication for system therapy with a PD-1/PD-L1 inhibitor according to clinical standards
- Patients without or with radiation of one or more metastases
- Age at least 18 years
Exclusion
- Melanoma patients
- Fertile patients who refuse effective contraception during study treatment
- Persistent drug and/or alcohol abuse
- Patients not able or willing to behave according to study protocol
- Patients in care
- Patients that are not able to speak German
- Patients which are imprisoned according to legal or governmental order
- Both gender are included into the study, a maximum age was not defined.
Key Trial Info
Start Date :
April 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04892849
Start Date
April 30 2021
End Date
December 31 2030
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany, 91054